

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7340557

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
YOUHEALTH BIOTECH, LIMITED	08/23/2018
RECEIVING PARTY DATA	
Name:	YOUHEALTH ONCOTECH, LIMITED
Street Address:	23 LIME TREE BAY AVENUE
Internal Address:	SUITE #4-210 GOVERNORS SQUARE
City:	GRAND CAYMAN
State/Country:	CAYMAN ISLANDS
Postal Code:	KYI-1209
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	10093986
CORRESPONDENCE DATA	
Fax Number:	(650)494-0792
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(650) 813-5726
Email:	cpicazomejia@mofa.com
Correspondent Name:	JOHN D CHAPMAN
Address Line 1:	MORRISON FOERSTER
Address Line 2:	755 PAGE MILL ROAD
Address Line 4:	PALO ALTO, CALIFORNIA 94304-1018
ATTORNEY DOCKET NUMBER:	16518-20002.00
NAME OF SUBMITTER:	JOHN D CHAPMAN
SIGNATURE:	/John D Chapman/
DATE SIGNED:	05/19/2022
Total Attachments: 6	
source=__ Document_YHB_to_YHO_assignment_16518#page1.tif	
source=__ Document_YHB_to_YHO_assignment_16518#page2.tif	
source=__ Document_YHB_to_YHO_assignment_16518#page3.tif	
source=__ Document_YHB_to_YHO_assignment_16518#page4.tif	

source=__Document_YHB_to_YHO_assignment_16518#page5.tif

source=__Document_YHB_to_YHO_assignment_16518#page6.tif

PATENT ASSIGNMENT

This Patent Agreement is entered into by and among the following parties on August 23, 2018:

- A. Laimeng Mardisen Medical Technology (Beijing) Co., Ltd., a company incorporated and existing under the law of China, having its registered address at Suite 1908, Building No. 10, No. 93 Yard Jianguo Road, Chaoyang District, Beijing, China, with its Chinese registration name as "莱萌麦迪森医疗技术(北京)有限公司" ("LAIMENG");
- B. Laboratory for Advanced Medicine, Inc., a company incorporated and existing under the law of Cayman Islands, having its registered office at Floor 4, Willow House, Cricket Square, P.O. Box 2804, Grand Cayman KY1-1112, Cayman Islands, with the registration number as 01-309517 ("LAM");
- C. YouHealth Biotech, Limited, a Cayman Islands corporation having its mailing address at Suite #4-210, Governors Square, 23 Lime Tree Bay Avenue, Grand Cayman KY1-1209, Cayman Islands (hereinafter referred to as the "Assignor"); and
- D. YouHealth Oncotech, Limited, a Cayman Islands Exempted Company with mailing address at Suite #4-210, Governors Square, 23 Lime Tree Bay Avenue, Grand Cayman KY1-1209, Cayman Islands, and registration number of which is 08-312777 (hereinafter referred to as the "Assignee", together the Assignor, LAM and LAMENG, collectively, the "Parties").

WHEREAS

- A. LAM, Guangzhou Youze Biological Pharmaceutical Technology Co., Ltd. ("Youze"), Rui Hou ("RUI"), and Rongling Xu, have entered into a Share Consolidation Agreement ("Share Consolidation Agreement") on March 31, 2018;
- B. LAM, Youze, Rui, and Rongling Xu, have entered into the Amendment to Share Consolidation Agreement on August 18, 2018 ("Amendment to Share Consolidation Agreement");
- C. The Assignor, Kang Zhang, RUI, Lianghong Zheng and University of California, San Diego ("UCSD") have entered into a Patent Assignment (regarding "Method and System For Determining Cancer Status", with the Docket number as "49697-701.601") on June 15, 2017 ("Prior Patent Assignment Agreement"); and
- D. LAIMENG, LAM, the Assignee and the other parties therein executed an Assignment Agreement of Share and Share Certificate at the same date of this Patent Assignment.

NOW, THEREFORE, in consideration of the mutual covenants and undertakings contained herein, shall be legally bound hereby, subject to and on the terms and conditions set forth herein, the Parties hereby agree as follows:

1. The Assignor does hereby sell, assign, transfer and convey unto the Assignee the Assignor's right and interest of patent(s) and patent application(s) regarding cancer set forth in Appendix I attached hereto ("Assigned Patents") and all the present and future improvements of such Assigned Patents in the United States and its territories and in foreign countries, or under any international convention, agreement, protocol, or treaty, the consideration of which is one dollar (in hand paid) (the "Assignment").
2. The Assignor does hereby covenant and agree to cooperate with the Assignee to enable the Assignee to enjoy to the fullest extent the right and interest herein sold, assigned, transferred and conveyed in the United States and its territories and in foreign countries, or under any international convention, agreement, protocol, or treaty.
3. The terms and covenants of this instrument shall inure to the benefit of the Assignee, its successors, assigns and other legal representatives, and shall be binding upon the Assignor, its respective heirs, assigns and other legal representatives.
4. The Assignee hereby confirm that, in the event that LAIMENG is not able to fully fulfill its obligations under Article 3 of the Amendment to Share Consolidation Agreement as defined in the preamble, this Patent Assignment shall be null and void ab initio no Assignment has occurred. The Assignee shall use its best efforts to execute all and any relevant documents and do all acts, deeds or things to ensure the Assignor shall retrieve all the right and interest regarding the Assigned Patents for nil cost from the Assignee.
5. The Assignor does hereby warrant, represent and covenant that the Assignor has not entered and will not enter into any assignment, contract or understanding in conflict herewith.
6. The Assignee hereby agrees, by its execution of this Patent Assignment and after the completion of the Assignment, to be bound by, all of the terms, provisions and conditions contained in the Prior Patent Assignment Agreement by which the Assignor was bound as a party thereon.

7. This instrument shall be interpreted and construed in accordance with the laws of the State of California, without regard to conflict of law principles. If any provision of this instrument is found to be illegal or unenforceable, the other provisions shall remain effective and enforceable to the greatest extent permitted by law. This instrument may be executed in counterparts, each of which is deemed an original, but all of which together constitute one and the same agreement.

[The remainder of this page has been left intentionally blank]

IN WITNESS WHEREOF, the Parties have executed and delivered this Patent Assignment as of the date written below.

~~YouHealth Biotech Limited~~ For and on behalf of
YouHealth Biotech Limited

Signature: Rui Hou

Name/Title: Rui Hou, Director Authorized Signature(s)

For and on behalf of
~~YouHealth Biotech Limited~~ YouHealth Biotech Limited

Signature: Kang Zhang

Name/Title: Kang Zhang, Director Authorized Signature(s)

For and on behalf of
~~YouHealth Oncotech Limited~~ YouHealth Oncotech Limited

Signature: Rui Hou Authorized Signature(s)

Name/Title: Rui Hou, Director

For and on behalf of
~~YouHealth Oncotech Limited~~ YouHealth Oncotech Limited

Signature: Kang Zhang

Name/Title: Kang Zhang, Director Authorized Signature(s)

M

IN WITNESS WHEREOF, the Parties have executed and delivered this Patent Assignment as of the date written below:

Laimeng Maidisen Medical Technology (Beijing) Co., Ltd. (黎明麦迪森医疗技术(北京)有限公司)

Signature: 

Name: Shu Li

Title: Legal Representative

Company Seal



Laboratory for Advanced Medicine, Inc.

For and on behalf of
Laboratory for Advanced Medicine, Inc.

Signature: 

Authorized Signature(s)

Name: Shu Li

Title: Director

Appendix I

Assigned Patents

Title	Matter	App. Number	Filing Date
Companion Diagnostic of Specific Cancer	49697-705.101	62/358,762	July 06, 2016
Breast and Ovarian Cancer Methylation Markers and Uses Thereof	49697-707.101	62/358,771	July 06, 2016
Colon Cancer Methylation Markers and Uses Thereof	49697-708.101	62/358,776	July 06, 2016
Liver Cancer Methylation Markers and Uses Thereof	49697-709.101	62/358,780	July 06, 2016
Lung Cancer Methylation Markers and Uses Thereof	49697-710.101	62/358,785	July 06, 2016
Solid Tumor Methylation Markers and Uses Thereof	49697-711.101	62/358,795	July 06, 2016
Method and System for Determining Cancer Status	49697-701.101	62/104,785	January 18, 2015
Method and System for Determining Cancer Status	49697-701.201	14/986,520	December 31, 2015
Method and System for Determining Cancer Status	49697-701.601	PCT/US2016/013716	December 31, 2015

H